Professional Title Krispy Kremes 16 Million Data Breach Settlement Deadline Approaches Who May Qualify Iran Pledges to Never Bow as Trump Rejects Peace Counteroffer Extending Middle East Instability Bitcoin Slips Below 76000 Eyes Weekly Loss Amid Liquidations and Interest Rate Uncertainty Digital Realty DLR Expands European Footprint with Inaugural Barcelona Data Center Russias Crude Shipments Steady Despite Latest US Sanctions Goldman Sachs Assesses Spotify Surges 13 on AI Music Deal with Universal Music and LongTerm Guidance PDF Solutions Q1 2026 Earnings Strong EPS Beat of 313 Drives Stock Uptick BETR Q1 2026 Earnings WiderthanExpected Loss as Company Navigates Challenging Market EVO Q1 2026 Earnings Shares Rise Despite Significant EPS Miss Mustang Bio Inc MBIO Q4 2024 Earnings Severe EPS Miss Highlights PreRevenue Biotech Challenges Solventum SOLV Q1 2026 Earnings EPS Beats Estimates by 734 Revenue Details Unreported HNST Q1 2026 Earnings EPS Misses Estimates but Stock Rallies on Operational Momentum Gesher Acquisition Corp II GSHR Holds Steady at 1038 as SPAC Consolidates Near Trust Value SORNW Holds Steady at 028 as Support and Resistance Levels Narrow AIOS Tech Inc AIOS Edges Higher in Quiet Trading Testing Key Support Levels FirstService Corporation FSV Edges Higher Testing NearTerm Resistance Allarity Therapeutics ALLR Slides 48 in Session Key Support Levels in Focus AI Economy Reshapes Job Market BlueCollar Skilled Trades Gain as College EntryLevel Roles Slow CPSS Q4 2025 Earnings Mixed Results as EPS Falls Short of Estimates DWave Quantum QBTS Surges 14 as Quantum Computing Momentum Builds OCFC Q1 2026 Earnings Earnings Per Share Surpasses Expectations Shares Edge Higher Shinhan Financial Group Q4 2025 Earnings EPS Falls Short as Net Income Pressures Mount OPCH Q1 2026 Earnings EPS Beat Drives Modest Stock Decline Arbe Robotics ARBE Q1 2026 Earnings EPS Misses Estimates Amid PreRevenue Development Phase Ingevity Corporation Q1 2026 Earnings EPS Surges 45 Above Consensus Stock Rises PRTC Q4 2024 Earnings EPS Misses Estimates as RD Expenses Continue to Weigh Corcept Therapeutics CORT Q1 2026 Earnings Severe Earnings Miss Overshadows Operational Developments